Advertisement

Transmural myocardial infarction. Focus on current strategies of myocardial reperfusion

  • G. Sinagra
  • G. Sabbadini
  • A. Perkan
Conference paper

Abstract

Although acute myocardial infarction (AMI) continues to be a major health problem with significant rates of morbidity and mortality [1], substantial improvements in the management of the disease have been achieved over the last decades, which in turn have lead to better outcomes of the patients [2].

Keywords

Acute Myocardial Infarction Acute Myocardial Infarction Fibrinolytic Therapy Primary Angioplasty Myocardial Reperfusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Hearth Association (1999) Heart and stroke facts: 1999 Statistical Supplement. American Hearth Association, Dallas, pp 1–36Google Scholar
  2. 2.
    Tunstall-Pedoe H, Mahonen M, Tolonen H, et al for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project (1999) Contribution of trends in survival and coronary-event rates to changes in coronary hearth disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 353:1547–1557PubMedCrossRefGoogle Scholar
  3. 3.
    Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671PubMedCrossRefGoogle Scholar
  4. 4.
    Fibrinolytic Therapy Trialists (FIT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from aU randomized trials of more than 1000 patients. Lancet 343:311–322Google Scholar
  5. 5.
    Weaver WD, Simes RJ, Betriu A et al for the Primary Coronary Angioplasty versus Tlirombolysis Collaboration Group (1997) Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative overview. JAMA 278:2093–2098Google Scholar
  6. 6.
    Braunwald E (1998) Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 352:1771–1774PubMedCrossRefGoogle Scholar
  7. 7.
    DeWood MA, Spores J, Notske R et al (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897–902PubMedCrossRefGoogle Scholar
  8. 8.
    Dorado DG, Theroux P, Elizaga J et al (1987) Myocardial infarction in the pig hearth model: infarct size and duration of coronary occlusion. Cardiovasc Res 21:537–544CrossRefGoogle Scholar
  9. 9.
    Flameng W, Lesaffre E, Vanhaecke J (1990) Determinants of infarct size in non-human primates. Basic Res Cardiol 85:392–403PubMedCrossRefGoogle Scholar
  10. 10.
    Reimer KA, Vander Heide RS, Richard VJ (1993) Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models. Am J Cardiol 72:13G-21GPubMedCrossRefGoogle Scholar
  11. 11.
    Califf RM, Bengtson JR (1994) Cardiogenic shock. N Engl J Med 330:1724–1730PubMedCrossRefGoogle Scholar
  12. 12.
    Hataway WR, Peterson ED, Wagner GS et al for the GUSTO-I Investigators (1998) Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. JAMA 279:387–391Google Scholar
  13. 13.
    Gruppo Italiano per lo Studio della Streptochinasi nellTnfarto miocardico (GISSI) (1987) Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 11:871–874Google Scholar
  14. 14.
    Mauri F, Franzosi MG, Maggioni AP et al (2002) Clinical value of 12-lead electrocardiography to predict the long-term prognosis of GISSI-1 patients. J Arn-Coll Cardiol 39; 1594–600CrossRefGoogle Scholar
  15. 15.
    Pfeffer MA, Braunwald E (1990) Ventricular remodeling after myocardial infarction, experimental observations and clinical implications. Circulation 81:1161–1172PubMedCrossRefGoogle Scholar
  16. 16.
    St John Sutton M, Pfeffer MA, Plappert T et al for the SAVE investigators (1994) Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction, the protective effect of Captopril. Circulation 89:68–75PubMedCrossRefGoogle Scholar
  17. 17.
    Kober L, Torp-Pedersen C, for the TRACE study group (1995) Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol 76:1–5PubMedCrossRefGoogle Scholar
  18. 18.
    Migrino RQ, Young JB, ElHs SG et al for the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators (1997) End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. Circulation 96: 116–121Google Scholar
  19. 19.
    Gruppo Italiano per lo Studio della Streptochinasi nellTnfarto miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397–402Google Scholar
  20. 20.
    The GUSTO Investigators (1993) An intemational randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682CrossRefGoogle Scholar
  21. 21.
    The Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO-III) Investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337:1118–1123CrossRefGoogle Scholar
  22. 22.
    ASSENT-2 Investigators (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet 354:716–722Google Scholar
  23. 23.
    Califf RM, White HD, Van de Werf F (1996) One-year results from the Global Utilization of Streptokinase and TPA for Occluded coronary arteries (GUSTO-I) trial. Circulation 94: 1233–1238PubMedCrossRefGoogle Scholar
  24. 24.
    Boersma E, Maas ACP, Deckers JW et al (1996) Eariy thrombolytic treatment in acute myocardial infarction: re-appraisal of the golden hour. Lancet 348:771–775PubMedCrossRefGoogle Scholar
  25. 25.
    Simes RJ, Topol EJ, Holmes DR Jr for the GUSTO-I Investigators (1995) Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation 91:1923–1928PubMedCrossRefGoogle Scholar
  26. 26.
    Ross AM, Coyne KS, Moreya E et al (1998) The extended mortality benefit of early postinfarction reperfusion. Circulation 97:1549–1555PubMedCrossRefGoogle Scholar
  27. 27.
    Lenderink T, Simoons ML, Van Es GA et al (1995) Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. Circulation 92:1110–1116PubMedCrossRefGoogle Scholar
  28. 28.
    Reiner JS, Lundergan CF, Fung A et al (1996) Evolution of eariy TIMI 2 flow after thrombolysis for acute myocardial infarction. Circulation 94:2441–2446PubMedCrossRefGoogle Scholar
  29. 29.
    Ohman EM, Califf RM, Topol EJ et al (1990) Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI study group. Circulation 82:781–791PubMedCrossRefGoogle Scholar
  30. 30.
    Brouwer MA, Bihncke JR, Veen G et al (1995) Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol 26:1440–1444Google Scholar
  31. 31.
    GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622CrossRefGoogle Scholar
  32. 32.
    LATE Study Group (1993) LATE Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 342:759–766CrossRefGoogle Scholar
  33. 33.
    3. EMERAS (Estudio Multicentrico Estreptoquinasa Repúblicas de America del Sur) Collaborative Group (1993) Randomized trial of late thrombolysis in acute myocardial infarction. Lancet 342:767–772CrossRefGoogle Scholar
  34. 34.
    Wong C-K, French JK, Andrews J et al (2002) Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. Eur Heart J 23:399–405PubMedCrossRefGoogle Scholar
  35. 35.
    Puma J A, Sketch MH Jr, Thompson TD et al (1999) Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. Am J Cardiol 83:482–487PubMedCrossRefGoogle Scholar
  36. 36.
    Kim CB, Braunwald E (1993) Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation 88:2426–2436Google Scholar
  37. 37.
    Braunwald E (1989) Myocardial reperfusion, limitation on infarct size, reduction of left ventricular dysfunction and improved survival. Should the paradigm be expanded? Circulation 79:441–444PubMedCrossRefGoogle Scholar
  38. 38.
    Hochman JS, Choo H (1987) Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 75:299–306PubMedCrossRefGoogle Scholar
  39. 39.
    Sager PT, Perlmutter RA, Rosenfeld LE et al (1988) Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol 12:19–24PubMedCrossRefGoogle Scholar
  40. 40.
    Gang ES, Lew AS, Hong M et al (1989) Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med 321:712–716PubMedCrossRefGoogle Scholar
  41. 41.
    Lavie CJ, O’Keefe JH Jr, Chesebro JH et al (1990) Prevention of late ventricular dilatation after acute myocardial infarction by successful thrombolytic reperfusion. Am J Cardiol 66:31–36PubMedCrossRefGoogle Scholar
  42. 42.
    Chesebro JH, Knatterud G, Roberts R et al (1987) Trombolysis In Myocardial Infarction (TIMI) Trial. Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142–154Google Scholar
  43. 43.
    Ito H, Okamura A, Iwakura K et al (1996) Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 93:1993–1999PubMedCrossRefGoogle Scholar
  44. 44.
    Kawamoto T, Yoshida K, Akasada T et al (1999) Can coronary blood flow velocity pattern after primary percutaneous transluminal coronary angiography predict recovery of regional left ventricular function in patients with acute myocardial infarction? Circulation 100:339–345PubMedCrossRefGoogle Scholar
  45. 45.
    Maes A, Van de Werf F, Nuyts J et al (1995) Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism and function at late follow-up. Circulation 92:2072–2078Google Scholar
  46. 46.
    Wu KC, Zerhouni EA, Judd RM et al (1998) Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97:765–772PubMedCrossRefGoogle Scholar
  47. 47.
    Beider MA de (2001) Acute myocardial infarction: failed thrombolysis. Heart 85:104–112CrossRefGoogle Scholar
  48. 48.
    Lemos JA de, Antman EM, Giugliano RP et al for the TIMI 14 Investigators (2000) ST segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Am J Cardiol 85:299–304Google Scholar
  49. 49.
    Fu Y, Goodman S, Chang WC et al (2001) Time to treatment influences the impact of ST-segment resolution on one-year prognosis. Insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Trial. Circulation 104:2653–2659PubMedCrossRefGoogle Scholar
  50. 50.
    White HD, French JK, Hamer AW et al (1995) Frequent reocclusion of patient infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. J Am Coll Cardiol 25:218–223PubMedCrossRefGoogle Scholar
  51. 51.
    Lincoff AM, Topol EJ (1993) Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 88:1361–1374PubMedCrossRefGoogle Scholar
  52. 52.
    Rezkalla SH, Kloner RA (2002) No-reflow phenomenon. Circulation 105:656–662PubMedCrossRefGoogle Scholar
  53. 53.
    Granger CB, White HD, Bates ER et al (1994) A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 74:1220–1228PubMedCrossRefGoogle Scholar
  54. 54.
    Lange RA, Hillis LD, Grines CL (1996) Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? N Engl J Med 335:1311–1317PubMedCrossRefGoogle Scholar
  55. 55.
    Grines CL, Browne KF, Marco J et al for the Primary Angioplasty in Myocardial Infarction Study Group (1993) A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 328:673–679Google Scholar
  56. 56.
    Zijlstra F, Boer MJ de, Hoomtje JCA et al (1993) A comparison of immediate angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 328:680–684PubMedCrossRefGoogle Scholar
  57. 57.
    Gibbons RJ, Holmes DR, Reeder GS et al for the Mayo Coronary Care Unit and Catheterization(1993) Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 328:685–691Google Scholar
  58. 58.
    Zijlstra F, Patel A, Jones M et al (2002) Clinical characteristics and outcome of patients with early (h), intermediate (2–4 h) and late (4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 23:550–557PubMedCrossRefGoogle Scholar
  59. 59.
    Antman EM, Braunwald E (2001) Acute myocardial infarction. In: Braunwald E, Zipes DP, Libby P (ed) Heart disease. A textbook of cardiovascular medicine 6th edn. Saunders, Philadelphia, pp 1114–1231Google Scholar
  60. 60.
    Califf RM, Topol EJ, Stack RS et al for the TAMI Study Group (1991) Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction-5 phase randomized trial. TAMI Study Group. Circulation 83:1543–1556Google Scholar
  61. 61.
    Ellis SG, Silva ER da, Heyndrickx GR et al for the RESCUE Investigators (1994) Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 90:2280–2284Google Scholar
  62. 62.
    Vermeer F, Oude Ophuis AJM, Berg EJ vd et al (1999) Prospective randomized comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to hospital without PTCA faciüties: a safety and feasibility study. Heart 82:426–431PubMedGoogle Scholar
  63. 63.
    Ellis SG, Silva ER da, Spaulding CM et al (2000) Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am Heart J 139:1046–1053Google Scholar
  64. 64.
    Grech ED, Sutton AGC, Campbell PG et al (2000) Reappraising the role of immediate intervention following thrombolytic recanalization in acute myocardial infarction. Am J Cardiol 86:400–405PubMedCrossRefGoogle Scholar
  65. 65.
    Topol EJ, Califf RM, George BS et al (1987) A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 317:581–588PubMedCrossRefGoogle Scholar
  66. 66.
    Simoons ML, Arnold AE, Betriu A et al (1988) Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1:197–203PubMedCrossRefGoogle Scholar
  67. 67.
    TIMI Study Group (1989) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. N Engl J Med 320:618–627CrossRefGoogle Scholar
  68. 68.
    Kleiman NS, Ohman EM, Califf RM et al (1993) Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 22:381–389PubMedCrossRefGoogle Scholar
  69. 69.
    The PARADIGM Investigators (1998) Combining thrombolysis with the platelet glycoprotein Ilb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction. J Am Coll Cardiol 32:2003–2010CrossRefGoogle Scholar
  70. 70.
    Ohman EM, Kleiman NS, Gocioch G et al for the IMPACT-AMI Investigators (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein Ilb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-con- trolled, dose-ranging trial. Circulation 95:846–854Google Scholar
  71. 71.
    Antman EM, Giugliano RP, Gibson GM et al for the TIMI-14 Investigators (1999) Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation 99:2720–2732Google Scholar
  72. 72.
    Strategies for Patency Enhancement in the Emergency Department (SPEED) Group (2000) Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 101:2988–2994Google Scholar
  73. 73.
    Lefkovits J, Ivanhoe RG, Califf RM et al for the EPIC Investigators (1996) Effects of platelet glycoprotein Ilb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 77:1045–1051Google Scholar
  74. 74.
    Brener S J, Barr LA, Burchenal JEB et al on behalf of the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators (1998) Randomized, placebo-controlled trial of platelet glycoprotein Ilb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98:734–741Google Scholar
  75. 75.
    Montalscot G, Barragan P, Wittenberg O et al (1999) Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: the ADMIRAL study, 30 day final results (abstract). Circulation 100 [Suppl I]: 1–87Google Scholar
  76. 76.
    Miller JM, Smalling R, Ohman EM et al for the GUSTO-ffl Investigators (1999) Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Am J Cardiol 84:779–784Google Scholar
  77. 77.
    ACC/AHA Practice Guidelines (1999) 1999 update: ACC/AHA Guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. Circulation 100:1016–1030Google Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • G. Sinagra
  • G. Sabbadini
  • A. Perkan

There are no affiliations available

Personalised recommendations